Skip to main content

Advertisement

SpringerLink
Log in

Cytoplasmic CD133 Expression is a Reliable Prognostic Indicator of Tumor Regression After Neoadjuvant Concurrent Chemoradiotherapy in Patients with Rectal Cancer

  • Colorectal Cancer
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Despite development in therapeutic strategies, such as neoadjuvant concurrent chemoradiotherapy (CCRT), the prognosis of colorectal cancer remains relatively poor. Cancer stem cells (CSC) with several characteristics can lead to therapeutic resistance. CD133 has been identified as a putative CSC marker in colorectal cancer; however, its functional role still needs elucidation. We verified the role of CD133 with emphasis on expression location and correlated the results of CD133 with clinical outcome in colorectal cancer.

Methods

We used immunohistochemistry to investigate the expression of CD133 in samples from 157 patients with colonic adenocarcinoma and from 76 patients with rectal adenocarcinoma who received neoadjuvant CCRT. We also correlated the expression location of CD133 with the clinicopathological parameters and prognosis.

Results

CD133 protein was variably overexpressed in colorectal cancer tissues and was present in three locations: apical and/or endoluminal surfaces, cytoplasm, and lumen. Cytoplasmic CD133 expression level correlated significantly with tumor local recurrence (P = 0.025) and survival of patients with colorectal cancer (P = 0.002), and correlated inversely with tumor regression grading (P = 0.021) after CCRT in patients with rectal cancer.

Conclusions

The expression of CD133 in the cytoplasm is closely associated with local recurrence and patient survival, and may provide a reliable prognostic indicator of tumor regression grading in patients with rectal cancer after CCRT. Cytoplasmic CD133 expression may also help identify the surviving cancer cells in areas with nearly total regression after CCRT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.

    Article  PubMed  Google Scholar 

  2. Park CY, Tseng D, Weissman IL. Cancer stem cell–directed therapies: recent data from the laboratory and clinic. Mol Ther. 2009;17:219–30.

    Article  PubMed  CAS  Google Scholar 

  3. Balch GC, De Meo A, Guillem JG. Modern management of rectal cancer: a 2006 update. World J Gastroenterol. 2006;12:3186–95.

    PubMed  Google Scholar 

  4. Guillem JG, Chessin DB, Cohen AM, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005;241:829–36.

    Article  PubMed  Google Scholar 

  5. Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688–96.

    Article  PubMed  Google Scholar 

  6. van den Brink M, Stiggelbout AM, van den Hout WB, et al. Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. J Clin Oncol. 2004;22:3958–64.

    Article  PubMed  Google Scholar 

  7. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.

    Article  PubMed  CAS  Google Scholar 

  8. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003;3:895–902.

    Article  PubMed  CAS  Google Scholar 

  9. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275–84.

    Article  PubMed  CAS  Google Scholar 

  10. Jordan CT, Guzman ML. Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene. 2004;23:7178–87.

    Article  PubMed  CAS  Google Scholar 

  11. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90:5002–12.

    PubMed  CAS  Google Scholar 

  12. O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106–10.

    Article  PubMed  Google Scholar 

  13. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon cancer-initiating cells. Nature. 2007;445:111–5.

    Article  PubMed  CAS  Google Scholar 

  14. Todaro M, Alea MP, Di Stefano AB, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2007;1:389–402.

    Article  PubMed  CAS  Google Scholar 

  15. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 2008;99:1285–9.

    Article  PubMed  CAS  Google Scholar 

  16. Lin EH, Hassan M, Li Y, et al. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer. 2007;110:534–42.

    Article  PubMed  CAS  Google Scholar 

  17. Du L, Wang H, He L, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008;14:6751–60.

    Article  PubMed  CAS  Google Scholar 

  18. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133− metastatic colon cancer cells initiate tumors. J Clin Invest. 2008;118:2111–20.

    PubMed  CAS  Google Scholar 

  19. Horst D, Scheel SK, Liebmann S, et al. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol. 2009;219:427–34.

    Article  PubMed  CAS  Google Scholar 

  20. Immervoll H, Hoem D, Sakariassen PØ, Steffensen OJ, Molven A. Expression of the “stem cell marker” CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer. 2008;8:48.

    Article  PubMed  Google Scholar 

  21. Saigusa S, Tanaka K, Toiyama Y, et al. Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer. Oncol Rep. 2010;24:345–50.

    Article  PubMed  CAS  Google Scholar 

  22. Saigusa S, Tanaka K, Toiyama Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol. 2009;16:3488–98.

    Article  PubMed  Google Scholar 

  23. Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23;8688–96.

    Article  PubMed  Google Scholar 

  24. Chen SF, Yang SF, Li JW, et al. Expression of fascin in oral and oropharyngeal squamous cell carcinomas has prognostic significance—a tissue microarray study of 129 cases. Histopathology. 2007;51:173–83.

    Article  PubMed  CAS  Google Scholar 

  25. Crawford NP, Colliver DW, Galandiuk S. Tumor markers and colorectal cancer: utility in management. J Surg Oncol. 2003;84;239–48.

    Article  PubMed  Google Scholar 

  26. Hongo K, Tanaka J, Tsuno NH, et al. CD133(−) cells, derived from a single human colon cancer cell line, are more resistant to 5-fluorouracil (FU) than CD133(+) cells, dependent on the β1-integrin signaling. J Surg Res. 2011. doi:10.1016/j.jss.2011.03.076.

  27. Choi D, Lee HW, Hur KY, et al. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol. 2009;15:2258–64.

    Article  PubMed  CAS  Google Scholar 

  28. Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A. Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci. 2008;99:1578–83.

    Article  PubMed  CAS  Google Scholar 

  29. Giebel B, Corbeil D, Beckmann J, et al. Segregation of lipid raft markers including CD133 in polarized human hematopoietic stem and progenitor cells. Blood. 2004;104:2332–8.

    Article  PubMed  CAS  Google Scholar 

  30. Sanchez-Madrid F, del Pozo MA. Leukocyte polarization in cell migration and immune interactions. EMBO J. 1999;18:501–11.

    Article  PubMed  CAS  Google Scholar 

  31. Lajtha LG. Stem cell concepts. Nouv Rev Fr Hematol. 1979;21:59–65.

    PubMed  CAS  Google Scholar 

  32. Wang Q, Chen ZG, Du CZ, Wang HW, Yan L, Gu J. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer. Histopathology. 2009;55:284–93.

    Article  PubMed  Google Scholar 

  33. Shia J, McManus M, Guillem JG, et al. Significance of acellular mucin pools in rectal carcinoma after neoadjuvant chemoradiotherapy. Am J Surg Pathol. 2011;35:127–34.

    Article  PubMed  Google Scholar 

  34. Casado E, García VM, Sánchez JJ, et al. A Combined strategy of SAGE and quantitative PCR cancer chemoradiotherapy response and outcome in rectal provides a 13-gene signature that predicts preoperative. Clin Cancer Res. 2011;17:4145–54.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This study was partly supported by the National Science Council, Republic of China, Grants NSC98-2314-B-016-019-MY3 and NSC 99-2320-B-039-028-MY3, and by the Tri-Service General Hospital, Grant TSGH-C100-007-009-10-S02.

Author information

Authors and Affiliations

  1. Division of Colon and Rectal Surgery, National Defense Medical Centre and Tri-Service General Hospital, Taipei, Taiwan

    Shu-Wen Jao MD, MS, Tsai-Yu Lee MD, MS & Chang-Chieh Wu MD, PhD

  2. Department of Dental Hygiene, China Medical University, Taichung, Taiwan

    Su-Feng Chen PhD

  3. Department of Otolaryngology-Head and Neck Surgery, National Defense Medical Centre and Tri-Service General Hospital, Taipei, Taiwan

    Yaoh-Shiang Lin MD

  4. Graduate Institute of Life Sciences, National Defense Medical Centre, Taipei, Taiwan

    Yun-Ching Chang PhD

  5. Department of Pathology, National Defense Medical Centre and Tri-Service General Hospital, Taipei, Taiwan

    Yun-Ching Chang PhD & Shin Nieh DDS, MS, MIAC

  6. Department of Pathology, Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan

    Jong-Shiaw Jin MD, PhD

Authors
  1. Shu-Wen Jao MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Su-Feng Chen PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yaoh-Shiang Lin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yun-Ching Chang PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tsai-Yu Lee MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chang-Chieh Wu MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jong-Shiaw Jin MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shin Nieh DDS, MS, MIAC
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yaoh-Shiang Lin MD or Shin Nieh DDS, MS, MIAC.

Additional information

Shin Nieh and Yaoh Shiang Lin contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jao, SW., Chen, SF., Lin, YS. et al. Cytoplasmic CD133 Expression is a Reliable Prognostic Indicator of Tumor Regression After Neoadjuvant Concurrent Chemoradiotherapy in Patients with Rectal Cancer. Ann Surg Oncol 19, 3432–3440 (2012). https://doi.org/10.1245/s10434-012-2394-3

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-012-2394-3

Keywords

Search

Navigation